➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Baxter
Express Scripts
AstraZeneca
Dow

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Fluzoparib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Fluzoparib?

Fluzoparib is an investigational drug.

There have been 31 clinical trials for Fluzoparib. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2020.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Lung Neoplasms, and Carcinoma, Ovarian Epithelial. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Tianjin Medical University Second Hospital, and Atridia Pty Ltd.

There are two US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for Fluzoparib
TitleSponsorPhase
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate CancerJiangsu HengRui Medicine Co., Ltd.Phase 2
Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung CancerJiangsu HengRui Medicine Co., Ltd.N/A
Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung CancerQilu Hospital of Shandong UniversityN/A

See all Fluzoparib clinical trials

Clinical Trial Summary for Fluzoparib

Top disease conditions for Fluzoparib
Top clinical trial sponsors for Fluzoparib

See all Fluzoparib clinical trials

US Patents for Fluzoparib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fluzoparib   Get Started Free Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN)   Get Started Free
Fluzoparib   Get Started Free Methods of using phthalazinone ketone derivatives Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fluzoparib

Drugname Country Document Number Estimated Expiration Related US Patent
Fluzoparib Australia AU2011288876 2030-08-09   Get Started Free
Fluzoparib Brazil BR112013002220 2030-08-09   Get Started Free
Fluzoparib Canada CA2806324 2030-08-09   Get Started Free
Fluzoparib China CN102372716 2030-08-09   Get Started Free
Fluzoparib China CN102686591 2030-08-09   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Medtronic
Express Scripts
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.